{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T14:09:45Z","timestamp":1770991785721,"version":"3.50.1"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,6,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective.<\/jats:title>\n                  <jats:p>No systematic study has been performed to evaluate the effect of cisapride on the QT interval in premature infants. Cisapride, which has recently been withdrawn by the Food and Drug Administration and is no longer an approved therapy, was commonly used for preterm infant care to improve the advance of enteral feedings and to reduce reflux and associated apnea. Our aim was to evaluate the effect of recommended doses of cisapride on the QT interval in this population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Study Design.<\/jats:title>\n                  <jats:p>Prospective blinded evaluation of electrocardiogram for QT, JT, QTc, and JTc measurements in 25 preterm infants before and after cisapride administration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Twelve of 25 infants (48%) developed repolarization abnormalities with cisapride administration: 32% of the infants (8\/25) studied had QTc prolongation (\u22650.450 seconds), whereas 10\/25 had JTc prolongation (\u22650.360 seconds). Preterm infants &amp;lt;32 weeks significantly prolonged their QTc interval from 0.41 \u00b1 0.02 to 0.44 \u00b1 0.02. The QTc and\/or JTc was prolonged in 54% of infants receiving 0.1 mg\/kg\/dose and 42% receiving 0.2 mg\/kg\/dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>The QTc and JTc interval significantly prolonged in preterm infants &amp;lt;32 weeks on the recommended dose of cisapride therapy. A QTc \u22650.450 seconds developed in 32% of infants treated with cisapride, whereas the JTc prolonged in 40%. A significant percentage of infants (54%) developed prolonged QTc intervals at a dose of 0.1 mg\/kg\/dose. From these data we conclude that there is a higher risk of prolongation of the QTc interval and risk of arrhythmias with greater prematurity.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.107.6.1313","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T23:55:51Z","timestamp":1092441351000},"page":"1313-1316","source":"Crossref","is-referenced-by-count":35,"title":["Cisapride Associated With QTc Prolongation in Very Low Birth Weight Preterm Infants"],"prefix":"10.1542","volume":"107","author":[{"given":"Anne","family":"Dubin","sequence":"first","affiliation":[{"name":"From the Divisions of Pediatric Cardiology and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrna","family":"Kikkert","sequence":"additional","affiliation":[{"name":"Leiden University School of Medicine, Leiden, The Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majid","family":"Mirmiran","sequence":"additional","affiliation":[{"name":"Neonatal and Development Medicine, Department of Pediatrics, Stanford University, Stanford, California;"},{"name":"Netherlands Institute for Brain Research, Amsterdam, The Netherlands; and the"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Ariagno","sequence":"additional","affiliation":[{"name":"Neonatal and Development Medicine, Department of Pediatrics, Stanford University, Stanford, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2001,6,1]]},"reference":[{"key":"2021121009494404000_B1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1542\/peds.103.2.469","article-title":"Cisapride. a survey of the frequency of use and adverse event in newborns.","volume":"103","author":"Ward","year":"1999","journal-title":"Pediatrics"},{"key":"2021121009494404000_B2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00005176-199905000-00018","article-title":"The use of cisapride in children.","volume":"28","author":"Shulman","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2021121009494404000_B3","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/00005176-199905000-00017","article-title":"The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology, and Nutrition.","volume":"28","author":"Vandenplas","year":"1999","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2021121009494404000_B4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1177\/106002809402800413","article-title":"Cisapride: a gastrointestinal prokinetic drug.","volume":"28","author":"Barone","year":"1994","journal-title":"Ann Pharmacother"},{"key":"2021121009494404000_B5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1161\/01.CIR.97.2.204","article-title":"Block of the rapid component of the delayed rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval.","volume":"97","author":"Drolet","year":"1998","journal-title":"Circulation"},{"key":"2021121009494404000_B6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0014-5793(97)01249-0","article-title":"A mechanism for the proarrhythmic effects of cisapride.","volume":"417","author":"Rampe","year":"1997","journal-title":"FEBS Lett"},{"key":"2021121009494404000_B7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/01.RES.78.1.15","article-title":"Developmental changes in ionic channel activity in the embryonic murine heart.","volume":"78","author":"Davies","year":"1996","journal-title":"Circ Res"},{"key":"2021121009494404000_B8","first-page":"H2088","article-title":"Identification and characteristics of the delayed rectifier K current in fetal mouse ventricular myocytes.","volume":"270","author":"Wang","year":"1996","journal-title":"Am J Physiol"},{"key":"2021121009494404000_B9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/01.RES.79.1.79","article-title":"Developmental changes in the delayed rectifier K channels in mouse heart.","volume":"79","author":"Wang","year":"1996","journal-title":"Circ Res"},{"key":"2021121009494404000_B10","first-page":"A2788","article-title":"Delayed maturation of cytochrome P 450 3A (CYP3A) activity in vivo in the first year of life.","volume":"47","author":"Leeder","year":"2000","journal-title":"Pediatr Res"},{"key":"2021121009494404000_B11","first-page":"A280","article-title":"Evidence of cisapride metabolism immaturity in neonates.","volume":"47","author":"Treluyer","year":"2000","journal-title":"Pediatr Res"},{"key":"2021121009494404000_B12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2165\/00003495-199447010-00008","article-title":"Cisapride: an updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.","volume":"47","author":"Wiseman","year":"1994","journal-title":"Drugs"},{"key":"2021121009494404000_B13","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1056\/NEJM199607253350416","article-title":"Cisapride and fatal arrhythmia.","volume":"335","author":"Wysowski","year":"1996","journal-title":"N Engl J Med"},{"key":"2021121009494404000_B14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinte.1995.00430070125014","article-title":"Long QT syndrome during high-dose cisapride.","volume":"155","author":"Bran","year":"1995","journal-title":"Arch Intern Med"},{"key":"2021121009494404000_B15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0022-3476(96)70409-2","article-title":"Cisapride-induced long QT interval.","volume":"128","author":"Lewin","year":"1996","journal-title":"J Pediatr"},{"key":"2021121009494404000_B16","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1542\/peds.101.6.1053","article-title":"Proarrhythmia associated with cisapride in children.","volume":"101","author":"Hill","year":"1998","journal-title":"Pediatrics"},{"key":"2021121009494404000_B17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-3476(98)70177-5","article-title":"Effects of cisapride on QT interval in children.","volume":"133","author":"Khongphatthanayothin","year":"1998","journal-title":"J Pediatr"},{"key":"2021121009494404000_B18","doi-asserted-by":"crossref","first-page":"F241","DOI":"10.1136\/fn.77.3.F241","article-title":"Effects of cisparide on QTc interval in neonates.","volume":"77","author":"Bernardini","year":"1997","journal-title":"Arch Dis Child"},{"key":"2021121009494404000_B19","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/0002-9149(94)90558-4","article-title":"Use of the rate-corrected JT interval for prediction of repolarization abnormalties in children.","volume":"74","author":"Berul","year":"1994","journal-title":"Am J Cardiol"},{"key":"2021121009494404000_B20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0010-4825(90)90013-F","article-title":"A note on the use of the intraclass correlation coefficient in the evaluation of agreement between two methods of measurement.","volume":"20","author":"Bland","year":"1990","journal-title":"Comput Biol Med"},{"key":"2021121009494404000_B21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0022-3476(97)70335-4","article-title":"Cisapride high dosage and long QT interval.","volume":"130","author":"Bedu","year":"1997","journal-title":"J Pediatr"},{"key":"2021121009494404000_B22","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1542\/peds.101.3.e9","article-title":"QT interval in children and infants receiving cisapride.","volume":"101","author":"Levine","year":"1998","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/107\/6\/1313\/895586\/1313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/107\/6\/1313\/895586\/1313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T21:53:31Z","timestamp":1639173211000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/107\/6\/1313\/66309\/Cisapride-Associated-With-QTc-Prolongation-in-Very"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6,1]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2001,6,1]]},"published-print":{"date-parts":[[2001,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.107.6.1313","relation":{},"ISSN":["1098-4275","0031-4005"],"issn-type":[{"value":"1098-4275","type":"electronic"},{"value":"0031-4005","type":"print"}],"subject":[],"published":{"date-parts":[[2001,6,1]]}}}